Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:5363
Name myxoid liposarcoma
Definition A liposarcoma that is characterized by the presence of a hypocellular spindle cell proliferation set in a myxoid background and has_material_basis_in chromosomal translocations.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer lipomatous cancer liposarcoma myxoid liposarcoma


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 amp Dovitinib myxoid liposarcoma sensitive detail...
FGFR2 amp Dovitinib + Trabectedin myxoid liposarcoma sensitive detail...
FGFR2 amp PD173074 myxoid liposarcoma sensitive detail...
FGFR2 amp Infigratinib myxoid liposarcoma sensitive detail...
FGFR2 amp PD173074 + Trabectedin myxoid liposarcoma sensitive detail...
FGFR2 amp Infigratinib + Trabectedin myxoid liposarcoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01506596 Phase II Pazopanib Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed
NCT02387125 Phase I CMB305 A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 Terminated
NCT02609984 Phase II Atezolizumab G305 + ID-LV305 Trial of CMB305 and Atezolizumab in Patients With Sarcoma Terminated
NCT02992743 Phase II NY-ESO-1-c259T A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma Recruiting
NCT03450122 Phase I Aldesleukin + CMB305 + Cyclophosphamide + ID-LV305 Aldesleukin + Cyclophosphamide Aldesleukin + Cyclophosphamide + ID-LV305 Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma Recruiting
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Recruiting
NCT04028063 Phase II Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting
NCT04044768 Phase II ADP-A2M4 cells Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Recruiting
NCT04044859 Phase I ADP-A2M4 cells Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors Recruiting